Eosinophilic Esophagitis (EoE): it's probably the most common allergic reaction you've never heard of. It's a condition that causes the tissues of the esophagus (the tube that connects the mouth to ...

Please provide your email address to receive an email when new articles are posted on . Children with eosinophilic esophagitis currently rely on elimination diets. The safety profile for this age ...

Experts at Cincinnati Children's play key roles in one trial that supports dupilumab use for children under 12 and another study showing no relief for people taking benralizumab. Both studies appear ...

“In EoE, PPIs are used for anti-inflammatory properties rather than acid suppression,” says Alex Koral, MD, a gastroenterologist and an associate professor of pediatric gastroenterology at Yale School ...

Elizabeth Spencer, MD, explains how a multidisciplinary team and open communication assist in implementing tailored treatment plans for children with eosinophilic esophagitis (EoE) and offers advice ...

Eosinophilic esophagitis (EoE) is no longer a rarity in European clinics. Diagnosed increasingly over the past three decades, EoE is commonly managed with pharmacotherapy, elimination diets, and, when ...

PHILADELPHIA (WPVI) -- Allergic reactions come in all varieties. One can even trigger a digestive disease which makes it hard to swallow. It's known as EOE - Eosinophilic Esophagitis. For more than 30 ...

Please provide your email address to receive an email when new articles are posted on . Other eosinophilic esophagitis treatments may have painful side effects. Dupilumab improved histologic, ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

About the Dupixent Pediatric Eosinophilic Esophagitis Trial The Phase 3, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in young children aged 1 to 11 ...

While dupilumab's use has been extended to children under 12, benralizumab shows no benefit to patients with eosinophilic esophagitis (EoE). Despite high hopes, a drug that wipes out the namesake cell ...

Despite high hopes, a drug that wipes out the namesake cell type associated with the disease eosinophilic esophagitis (EoE) doesn't make patients feel better and doesn't reverse tissue damage in their ...